CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zealand Pharma A/S is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zealand Pharma A/S
Sydmarken 11
Phone: +45 88773600p:+45 88773600 SOEBORG, 2860  Denmark Ticker: ZEALZEAL
Business Summary
Zealand Pharma A/S is a Denmark-based biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines. The Company's activities are organized around three therapeutic areas: Obesity and Related Comorbidities, which includes obesity and metabolic disease therapies; Rare Diseases, which develops treatments for congenital hyperinsulinism and short bowel syndrome; and Inflammation, which focuses on therapies for chronic inflammatory and autoimmune diseases. Zealand Pharma conducts research and development activities internally and through strategic collaborations with pharmaceutical partners, including Roche and Boehringer Ingelheim.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Alf G.Nicklasson 71 4/21/2015 4/21/2015
President, Chief Executive Officer, Member of the Executive Management Adam S.Steensberg 52 3/30/2022 3/19/2015
Independent Vice Chairman of the Board Kirsten A.Drejer 70 4/4/2019 4/19/2018
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Valeritas Holdings, Inc. 750 US Highway 202 Bridgewater NJ United States
Valeritas, Inc. 750 US Highway 202 Ste 600 BRIDGEWATER NJ United States

Business Names
Business Name
0NZU
Encycle Therapeutics Inc.
Valeritas, Inc.
10 additional Business Names available in full report.

General Information
Number of Employees: 578 (As of 6/30/2026)
Outstanding Shares: 69,259,276 (As of 6/30/2026)
Shareholders: 72,980
Stock Exchange: CPH
Fax Number: +45 88773898


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, September 11, 2026